Marker Therapeutics, Inc.
MRKR
$1.42
-$0.04-2.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -51.00% | -35.99% | -26.34% | -71.94% | 113.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -51.00% | -35.99% | -26.34% | -71.94% | 113.14% |
| Cost of Revenue | -57.91% | -32.42% | 78.86% | 21.76% | 94.33% |
| Gross Profit | 63.40% | 27.98% | -184.33% | -109.34% | -81.60% |
| SG&A Expenses | -17.57% | 19.78% | -17.23% | 12.40% | -25.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.13% | -22.10% | 47.30% | 18.76% | 53.05% |
| Operating Income | 51.21% | 10.97% | -84.61% | -63.02% | -31.44% |
| Income Before Tax | 54.63% | 13.41% | -83.13% | -85.82% | -38.41% |
| Income Tax Expenses | -130.40% | -- | -- | -- | 1,251.35% |
| Earnings from Continuing Operations | 55.62% | 13.41% | -83.13% | -85.82% | -40.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.62% | 13.41% | -83.13% | -85.82% | -36.91% |
| EBIT | 51.21% | 10.97% | -84.61% | -63.02% | -31.44% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 78.96% | 53.88% | -17.00% | -48.92% | -32.64% |
| Normalized Basic EPS | 78.48% | 53.93% | -16.98% | -33.75% | -34.04% |
| EPS Diluted | 78.96% | 53.85% | -16.00% | -48.92% | -32.64% |
| Normalized Diluted EPS | 78.48% | 53.93% | -16.98% | -33.75% | -34.04% |
| Average Basic Shares Outstanding | 110.94% | 87.80% | 56.50% | 24.76% | 3.23% |
| Average Diluted Shares Outstanding | 110.94% | 87.80% | 56.50% | 24.76% | 3.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |